Retatrutide, a experimental dual stimulator of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) target, is showing promising data in preliminary patient studies. Current https://bookmarkforest.com/story21286037/retatrutide-emerging-research-and-possible-clinical-roles